Sugi Predict

Sugi Predict / Compounds / SCHEMBL14745827

SCHEMBL14745827

SCHEMBL14745827

CCOC(=O)c1c(F)c2cc(Br)ccc2n1C

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ELANE P08246 4/20 0.50
▸ SMN1; SMN2 Q16637 4/20 0.50
▸ ALDH1A1 P00352 3/20 0.50
▸ LMNA P02545 3/20 0.50
▸ MAPT P10636 2/20 0.48
▸ GABRA1 P14867 1/20 0.43
▸ GABRB1 P18505 1/20 0.43
▸ GABRA3 P34903 1/20 0.43
▸ GABRB2 P47870 1/20 0.43
▸ ALOX5 P09917 2/20 0.43
▸ ATM Q13315 1/20 0.43
▸ APAF1 O14727 1/20 0.42
▸ SMAD3 P84022 1/20 0.42
▸ KDM4E B2RXH2 2/20 0.41
▸ GAA P10253 1/20 0.41
▸ HPGD P15428 1/20 0.41
▸ NPC1 O15118 1/20 0.41
▸ RAB9A P51151 1/20 0.41
▸ RXFP1 Q9HBX9 1/20 0.40
▸ HSD17B10 Q99714 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14758276 0.84 MAPT (0.48) SMN1; SMN2ALDH1A1LMNAMAPTALOX5
SCHEMBL21954348 0.78 ALDH1A1 (0.63) SMN1; SMN2ALDH1A1LMNAMAPTAPAF1
SCHEMBL3206351 0.76 SMN1; SMN2 (0.56) ELANESMN1; SMN2ALDH1A1LMNAMAPT
SCHEMBL4615959 0.76 TSHR (0.53) ELANESMN1; SMN2ALDH1A1LMNAMAPT
SCHEMBL18548900 0.75 LMNA (0.58) ELANESMN1; SMN2ALDH1A1LMNAMAPT
SCHEMBL14803920 0.75 ELANE (0.67) ELANESMN1; SMN2ALDH1A1LMNAMAPT
SCHEMBL22528411 0.74 ALDH1A1 (0.66) SMN1; SMN2ALDH1A1LMNAMAPTALOX5
SCHEMBL25941571 0.74 SMN1; SMN2 (0.54) ELANESMN1; SMN2ALDH1A1LMNAALOX5
SCHEMBL15966805 0.74 ALDH1A1 (0.77) SMN1; SMN2ALDH1A1LMNAMAPTATM
SCHEMBL1096993 0.74 MCL1 (0.64) ELANESMN1; SMN2ALDH1A1LMNAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12637426-B2 1-cyano-pyrrolidine compounds as USP30 inhibitors MISSION THERAPEUTICS LIMITED (GB) 2026-05-26 — — US disclosed
CN-112707893-B 1-cyanopyrrolidine compounds as USP30 inhibitors 特殊治疗有限公司 2023-10-31 — — CN disclosed
US-20220251041-A1 1-CYANO-PYRROLIDINE COMPOUNDS AS USP30 INHIBITORS MISSION THERAPEUTICS LTD (GB) 2022-08-11 — — US disclosed
US-11390584-B2 1-cyano-pyrrolidine compounds as USP30 inhibitors MISSION THERAPEUTICS LIMITED (GB) 2022-07-19 — — US disclosed
EP-3943490-A1 1-CYANO-PYRROLIDINE COMPOUNDS AS USP30 INHIBITORS Mission Therapeutics Limited (GB) 2022-01-26 — — EP disclosed
US-11066365-B2 1-cyano-pyrrolidine compounds as USP30 inhibitors MISSION THERAPEUTICS LIMITED (GB) 2021-07-20 — — US disclosed
EP-3277677-B9 1-CYANO-PYRROLIDINE COMPOUNDS AS USP30 INHIBITORS MISSION THERAPEUTICS LTD (GB) 2021-07-14 — — EP disclosed
US-11053198-B2 1-cyano-pyrrolidine compounds as USP30 inhibitors MISSION THERAPEUTICS LIMITED (GB) 2021-07-06 — — US disclosed
EP-3842427-A1 1-CYANO-PYRROLIDINE COMPOUNDS AS USP30 INHIBITORS Mission Therapeutics Limited (GB) 2021-06-30 — — EP disclosed
CN-112707893-A 1-cyanopyrrolidine compounds as USP30 inhibitors 特殊治疗有限公司 2021-04-27 — — CN disclosed
WO-2016156816-A1 1-CYANO-PYRROLIDINE COMPOUNDS AS USP30 INHIBITORS MISSION THERAPEUTICS LIMITED (GB) 2016-10-06 — — WO disclosed
WO-2016156816-A1 1-CYANO-PYRROLIDINE COMPOUNDS AS USP30 INHIBITORS MISSION THERAPEUTICS LIMITED (GB) 2016-10-06 — — WO disclosed
US-9409905-B2 Antibacterial compounds and methods for use PTC THERAPEUTICS, INC. (US) 2016-08-09 — — US disclosed
US-9409905-B2 Antibacterial compounds and methods for use PTC THERAPEUTICS, INC. (US) 2016-08-09 — — US disclosed
US-9409905-B2 Antibacterial compounds and methods for use PTC THERAPEUTICS, INC. (US) 2016-08-09 — — US disclosed
US-20150038437-A1 ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE PTC THERAPEUTICS, INC. (US) 2015-02-05 — — US disclosed
US-20150038437-A1 ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE PTC THERAPEUTICS, INC. (US) 2015-02-05 — — US disclosed
US-20150038437-A1 ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE PTC THERAPEUTICS, INC. (US) 2015-02-05 — — US disclosed
EP-2750504-A1 ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE PTC Therapeutics, Inc. (US) 2014-07-09 — — EP disclosed
WO-2013033258-A1 ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE PTC THERAPEUTICS, INC. (US) 2013-03-07 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11066365-B2 1-cyano-pyrrolidine compounds as USP30 inhibitors USP30, USP20, USP10 ELANE 3743/4885SMN1; SMN2 3214/4885ALDH1A1 1172/4885
US-20220251041-A1 1-CYANO-PYRROLIDINE COMPOUNDS AS USP30 INHIBITORS USP30, USP20, USP10 ELANE 2986/4885SMN1; SMN2 3078/4885ALDH1A1 1264/4885
US-11053198-B2 1-cyano-pyrrolidine compounds as USP30 inhibitors USP30, USP20, USP10 ELANE 2986/4885SMN1; SMN2 3078/4885ALDH1A1 1264/4885
US-20150038437-A1 ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE MRPL21, SLC11A2, CLPP ELANE 14/4885SMN1; SMN2 4224/4885ALDH1A1 3792/4885
US-12637426-B2 1-cyano-pyrrolidine compounds as USP30 inhibitors USP30, USP1, USP10 ELANE 3480/4885SMN1; SMN2 2487/4885ALDH1A1 1185/4885
US-11390584-B2 1-cyano-pyrrolidine compounds as USP30 inhibitors USP30, USP20, USP10 ELANE 2909/4885SMN1; SMN2 3239/4885ALDH1A1 1220/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.